CYTODEL LLC logo

CYTODEL LLC

Early biopharma with technology platform that delivers therapeutic Abs to the inside of neurons. Also bioengineers BoNT pharmaceuticals w/ tailored indications CytoDel is a biotechnology company developing Botulinum neurotoxin (BTX) for the treatment of nervous system disorders, chronic pain and neurodegenerative diseases.

0
Management
0
Technology
0
Deals/Partnering
0
Research Pipeline
0
Funding
BioStartup's Score 0 / 50

KEY DETAILS

Websitehttps://www.cytodel.com
Founded2012
Disease Focus
Development Stage
STOCK CODENon Listed
Address
423 W 127th StreetNew York, NY 10027
NEW YORK
United States
Email
Contact Number
+1 646 820 0066

[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://www.linkedin.com/company/cytodel-llc” connections=”true” suffix=””]

CytoDel possesses a proprietary platform for bioengineering recombinant Botulinum neurotoxin (BTX). BTX protein is extremely toxic throughout its production, and very sensitive to mechanical forces that can affect its potency. BTX is a commercially valuable protein for use in neurological, musculoskeletal and aesthetic medicine, and for the very specific targeting of therapeutic agents to the inside of neurons.

In Jan 2018, CytoDel, Inc. completed series A Convertible Preferred Stock to institutional accredited investors, led by a private equity fund. The other deails remain undisclosed.